BioCentury
ARTICLE | Company News

Amgen, Novartis biosimilars news

May 18, 2015 7:00 AM UTC

Novartis’ Sandoz Inc. generics unit filed a statement with the U.S. Court of Appeals for the Federal Circuit (CAFC) requesting a $179.4 million bond from Amgen to compensate for losses due to the delayed launch of Zarxio filgrastim-sndz, Sandoz’s biosimilar of Amgen’s Neupogen filgrastim.

Earlier this month, the CAFC granted Amgen’s motion for a preliminary injunction that will delay Zarxio’s launch until the court resolves Amgen’s appeal in the companies’ dispute concerning their exchange of information about the biosimilar. Sandoz had planned to launch Zarxio on May 11 (see BioCentury, May 11). ...